Cyxone Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Kjell Stenberg

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	1.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Kjell Stenberg (72 yo)

less than a year

Mandato

Dr. Kjell G. Stenberg, Ph D., is one of the Co-Founders and has been the Chief Executive Officer of Cyxone AB (publ) since April 22, 2024. He previously served as Chief Executive Officer of Cyxone AB (publ...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Kjell Stenberg	Chief Executive Officer	less than a year	Nessun dato	Nessun dato
Henrik Hang	Interim Chief Financial Officer	less than a year	Nessun dato	Nessun dato
Malin Lindskog	Chief Financial Officer - On Leave	less than a year	Nessun dato	Nessun dato

0.8yrs

Durata media

42yo

Età media

Gestione esperta: Il team dirigenziale di 4CX non è considerato esperto (durata media 0.8 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Christian Gruber	Chairman of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Maarten Kraan	Senior Scientific Advisor & Director	4.3yrs	Nessun dato	Nessun dato
Rikard Holmdahl	Senior Scientific Advisor	less than a year	Nessun dato	Nessun dato
Michael Oredsson	Independent Chairman	1.5yrs	SEK 200.00k	0.17% € 1.5k
Andrew Scorey	Independent Director	1.5yrs	SEK 100.00k	0.17% € 1.5k
Jurgen Reess	Independent Director	1.5yrs	SEK 100.00k	Nessun dato

1.5yrs

Durata media

62.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 4CX non è considerato esperto (durata media del mandato 1.5 anni), il che suggerisce un nuovo consiglio.

Cyxone Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Cyxone AB (publ) Announces Chief Executive Officer Changes

Cyxone Announces CFO Changes

Cyxone AB (publ) Announces Board Changes

Cyxone AB (Publ) Appoints Carl-Magnus Högerkorp as Permanent CEO

Cyxone AB (Publ) Announces That the Members of the Nomination Committee for Annual General Meeting 2023

Cyxone Appoints Erika Samuelsson as Chief Development Officer

Recent updates

Cyxone AB (publ) to Report Q3, 2024 Results on Nov 29, 2024

Second quarter 2024 earnings released: kr0.02 loss per share (vs kr0.045 loss in 2Q 2023)

Cyxone AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 6.297851 million.

Cyxone AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 23.03211 million.

Cyxone AB (publ) Provides an Update on its Research and Development Program

First quarter 2024 earnings released: kr0.02 loss per share (vs kr0.062 loss in 1Q 2023)

Cyxone AB (publ) Announces Chief Executive Officer Changes

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

New major risk - Financial position

Cyxone AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024

Cyxone AB (publ) to Report Q4, 2024 Results on Feb 25, 2025

New major risk - Revenue and earnings growth

Cyxone AB (publ) to Report Q3, 2023 Results on Nov 21, 2023

Cyxone Announces CFO Changes

Cyxone AB (publ) Announces Board Changes

Cyxone AB (Publ) Receives Ethical and Regulatory Approval from Georgia to Conduct Clinical Phase 2B Study in RA

Cyxone AB (Publ) Advances the Patent Portfolio for Rabeximod

Cyxone AB (publ) to Report Fiscal Year 2023 Results on Feb 23, 2024

Cyxone AB (Publ) Appoints Carl-Magnus Högerkorp as Permanent CEO

Cyxone (publ) Receives Ethical and Regulatory Approval from Hungary to Start Clinical Phase 2b Study in RA

Cyxone AB (Publ) Announces That the Members of the Nomination Committee for Annual General Meeting 2023

Cyxone Appoints Erika Samuelsson as Chief Development Officer

Cyxone AB (publ) Receives Regulatory Approval to Start Clinical Phase 2B Study in RA

Cyxone AB (Publ) Appoints Erika Samuelsson as Chief Development Officer

Cyxone AB (Publ) Announces CFO Changes

Cyxone AB (publ) to Report Q3, 2022 Results on Oct 27, 2023

Cyxone Files Submission to Start Clinical Phase 2B Study in Poland and Georgia

Cyxone Receives Pre-IND Response from the US FDA regarding RA study

Cyxone (Publ) Files Regulatory Submission to Start Clinical Phase 2B Study with Rabeximod

Cyxone Announces Executive Changes

Cyxone AB Announces Promising T20k/Kora Combination Therapy Efficacy in Preclinical Therapeutic Model of MS

Safety Confirmation and Observed Trends in Covid-19 Study Build Further Confidence in Cyxone's Rheumatoid Arthritis Program

Cyxone (publ) Announces Resignation of Cornel Pater as Chief Medical Officer

Cyxone (publ) Reports Publication of Four Patent Applications Pertaining to its Drug Candidate Rabeximod

Cyxone (publ) Initiates Early Operations with Global Contract Research Organization to Conduct Phase 2B Trial in Rheumatoid Arthritis

Cyxone Files Patent Application with Potential to Extend Market Exclusivity of the Drug Candidate Rabeximod

Cyxone AB (Publ) Comments on the Covid-19 Study Results

Cyxone (Publ) Presents Top-Line Results from A Phase 2 Study of Rabeximod in Covid-19 Patients

Cyxone AB (Publ) Expects to Communicate Top-Line Results from A Recently Concluded Phase 2 Trial of Its Drug Candidate Rabeximod in Covid-19 Patients

CFO & Interim CEO Ola Skanung has left the company

Cyxone Announces Rabeximod in Covid-19 Phase 2 Trial Closed and Data to Be Reports in Third Quarter

Cyxone Explores Expanding into New Regions to Mitigate Potential Delay in Covid-19 Trial Completion

Chief Operating Officer has left the company

Cyxone Joins Forces with Leading Rheumatoid Arthritis Expert

Cyxone Initiates Feasibility Preclinical Studies to Optimize Path Forward for Multiple Sclerosis Drug Candidate T20K

Cyxone AB (publ) to Report Q4, 2021 Results on Feb 11, 2022

Cyxone (publ.) Reports First Covid-19 Patient Screened in Phase 2 Clinical Trial of Rabeximod

Cyxone AB (publ), Annual General Meeting, Jun 03, 2021

Cyxone AB (publ) Files an IND in the US with Rabeximod Following Positive Feed-Back from Pre-IND Meeting with the FDA

New 90-day low: €0.48

Cyxone AB (publ) Files Patent Application to Extend Exclusivity of Rabeximod

New 90-day low: €0.49

Cyxone Announces Expanded Plans for Rabeximod

New 90-day low: €0.50

Cyxone AB (Publ) Revises the Development Plan for Rabeximod

New 90-day high - €0.71

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media